The blockade of TIM-3 is also a promising approach for the treatment of hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [17,55,56,57]. The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.